Search

380 Result(s)
Sort by

empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Netherton Syndrome

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
The Angels Initiative

The Angels Initiative

The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
Listen to the sounds disrupting farms worldwide

Listen to the sounds disrupting farms worldwide

A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
sustainably fighting rabies info hub

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
ATM-Ranking-2021

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
BI_X_Shanghai

BI_X_Shanghai

Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
STOP Rabies: moving towards elimination

STOP Rabies: moving towards elimination

Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.